RepliCel

Clinical Data Published on Autologous Cell Therapy for Skin Rejuvenation

Autologous cell therapy shows promise

Clinical data from a randomized, placebo-controlled, Phase-I study published on September 11, 2019 in Skin Pharmacology and Physiology revealed that RCS-01, an autologous cell therapy, is well tolerated and might reverse the effects of aging skin through a gene expression response consistent with an improvement of extracellular matrix (ECM) homeostasis.

RepliCel Dermal Injection Technologies Receive U.S. Patent

Replicel Receives U.S. Patent for RCI-02

RepliCel Life Sciences has been granted a U.S. patent (No. 9,616,182) covering significant components of its novel, multi-needle dermal injection device. The patent relates to technologies designed to enable better control and repeatable consistency of needle action and product deposition. The patent also relates to the element designed to numb the skin prior to injection with the intended effect of reducing, if not eliminating, the need for local anesthetic prior to aesthetic injection procedures.